Olema Oncology Secures $250M Funding and Novartis Partnership for Phase 3 Breast Cancer Trial
核心洞察
Olema Oncology has secured a $250 million private placement to advance its clinical programs, including the Phase 3 OPERA-02 trial.
A collaboration with Novartis will provide ribociclib for the OPERA-02 trial, evaluating palazestrant in combination for ER (搜索)+/HER2 (搜索)- metastatic breast cancer (搜索).
The OPERA-02 trial is expected to begin in mid-2025, with approximately 1,000 patients, and Olema retains global commercial rights to palazestrant.
Olema Oncology has announced a clinical trial collaboration with Novartis and a $250 million private placement to advance its pipeline of targeted breast cancer (搜索) therapies. The collaboration focuses on a Phase 3 trial evaluating Olema's palazestrant in combination with Novartis' ribociclib for the treatment of ER (搜索)+/HER2 (搜索)- metastatic breast cancer.
The $250 million private placement, with participation from new and existing investors including Adage Capital Partners, Bain Capital Life Sciences, and others, will support the OPERA-02 trial, the ongoing Phase 3 OPERA-01 trial, and a Phase 1/2 study of OP-3136. The funding extends Olema's operational runway beyond key milestones through 2026.
OPERA-02 Trial Details
The collaboration with Novartis includes a supply agreement for ribociclib, which will be used in the planned Phase 3 OPERA-02 trial. This trial will evaluate the combination of palazestrant and ribociclib in approximately 1,000 patients with ER (搜索)+/HER2 (搜索)- metastatic breast cancer (搜索). Olema retains global commercial rights to palazestrant, while jointly owning the clinical data and inventions from the trial with Novartis. Trial initiation is expected in mid-2025.
Palazestrant (OP-1250): A Novel ER Antagonist and Degrader
Palazestrant (OP-1250) is an orally available small molecule with dual activity as both a complete estrogen receptor (ER (搜索)) antagonist (CERAN) and selective ER degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2 (搜索)-) breast cancer (搜索). Preclinical studies have shown that palazestrant completely blocks ER-driven transcriptional activity in both ESR1 wild-type and mutant forms of breast cancer.
Clinical Development and FDA Fast Track Designation
Palazestrant has demonstrated anti-tumor activity, favorable pharmacokinetics, and tolerability in ongoing clinical trials for advanced or metastatic ER (搜索)+/HER2 (搜索)- breast cancer (搜索). It has also shown combinability with CDK4/6 inhibitors. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to palazestrant for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.
Current Treatment Landscape and Unmet Needs
The treatment landscape for ER (搜索)+/HER2 (搜索)-negative metastatic breast cancer (搜索) has evolved with the introduction of targeted therapies like CDK4/6 inhibitors (ribociclib, palbociclib, abemaciclib) in combination with endocrine therapies. However, resistance to endocrine therapy remains a significant challenge. Palazestrant, with its dual mechanism of action, aims to address this unmet need by more effectively targeting ER-driven cancers, including those that have developed resistance.
Financial Implications and Future Outlook
The $250 million private placement strengthens Olema's financial position, enabling the company to fund its clinical programs through key milestones. This includes the OPERA-01 Phase 3 data expected in 2026, initial data from the OP-3136 Phase 1/2 study, and the execution of the Phase 3 OPERA-02 clinical trial. The collaboration with Novartis and the financial resources secured position Olema to potentially improve outcomes for women living with breast cancer (搜索).